Long-term survival after radiotherapy alone

Radiation Therapy Oncology Group prostate cancer trials

Mack Roach, Jiandong Lu, Miljenko V. Pilepich, Sucha O. Asbell, Mohammed Mohiuddin, Roger Terry, David Grignon

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Purpose: We assess the relative importance of the several pretreatment characteristics in predicting death from prostate cancer in patients treated with curative intent with external beam radiotherapy alone. Materials and Methods: Patients entered on 4 prospective phase III randomized trials conducted by the Radiation Therapy Oncology Group between 1975 and 1992 were selected for this analysis if they were deemed evaluable and eligible for the trial, they had received no hormonal therapy with initial treatment and followup information was available. A disease specific survival event was declared if death was certified as due to prostate cancer, complications of treatment or unknown causes with clinically active malignancy. Median followup for patients treated on early and late studies exceeded 11 and 6 years, respectively. Results: Most of the patients (1,557) had tumors clinically staged as T3 (59%), and 87 (36%) with clinically staged T1-2 tumors had pathologically positive lymph nodes. On multivariate analysis Gleason score, clinical stage and nodal status were associated with a less favorable overall and disease specific survival, whereas others factors, such as age and race, were not. A Gleason score of 8 to 10 was associated with a high risk of dying of prostate cancer in the first 5 years (risk ratio 20.0, p = 0.0001). The 10-year disease specific survival for patients with a Gleason score of 2 to 5, 6 to 7 and 8 to 10 was 87, 75 and 44%, respectively, following radiotherapy. Based on published reports these rates were higher than expected with observation alone. Conclusions: In the first 10 years Gleason score was the single most important predictor of death. Gleason score should be incorporated into the current clinical staging system.

Original languageEnglish (US)
Pages (from-to)864-868
Number of pages5
JournalJournal of Urology
Volume161
Issue number3
DOIs
StatePublished - Mar 1999
Externally publishedYes

Fingerprint

Radiation Oncology
Neoplasm Grading
Prostatic Neoplasms
Radiotherapy
Survival
Neoplasms
Therapeutics
Multivariate Analysis
Lymph Nodes
Odds Ratio
Observation

Keywords

  • Prostate neoplasms
  • Radiotherapy
  • Survival rate

ASJC Scopus subject areas

  • Urology

Cite this

Long-term survival after radiotherapy alone : Radiation Therapy Oncology Group prostate cancer trials. / Roach, Mack; Lu, Jiandong; Pilepich, Miljenko V.; Asbell, Sucha O.; Mohiuddin, Mohammed; Terry, Roger; Grignon, David.

In: Journal of Urology, Vol. 161, No. 3, 03.1999, p. 864-868.

Research output: Contribution to journalArticle

Roach, Mack ; Lu, Jiandong ; Pilepich, Miljenko V. ; Asbell, Sucha O. ; Mohiuddin, Mohammed ; Terry, Roger ; Grignon, David. / Long-term survival after radiotherapy alone : Radiation Therapy Oncology Group prostate cancer trials. In: Journal of Urology. 1999 ; Vol. 161, No. 3. pp. 864-868.
@article{5cbb230956374213bcbf9db9bf601de1,
title = "Long-term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials",
abstract = "Purpose: We assess the relative importance of the several pretreatment characteristics in predicting death from prostate cancer in patients treated with curative intent with external beam radiotherapy alone. Materials and Methods: Patients entered on 4 prospective phase III randomized trials conducted by the Radiation Therapy Oncology Group between 1975 and 1992 were selected for this analysis if they were deemed evaluable and eligible for the trial, they had received no hormonal therapy with initial treatment and followup information was available. A disease specific survival event was declared if death was certified as due to prostate cancer, complications of treatment or unknown causes with clinically active malignancy. Median followup for patients treated on early and late studies exceeded 11 and 6 years, respectively. Results: Most of the patients (1,557) had tumors clinically staged as T3 (59{\%}), and 87 (36{\%}) with clinically staged T1-2 tumors had pathologically positive lymph nodes. On multivariate analysis Gleason score, clinical stage and nodal status were associated with a less favorable overall and disease specific survival, whereas others factors, such as age and race, were not. A Gleason score of 8 to 10 was associated with a high risk of dying of prostate cancer in the first 5 years (risk ratio 20.0, p = 0.0001). The 10-year disease specific survival for patients with a Gleason score of 2 to 5, 6 to 7 and 8 to 10 was 87, 75 and 44{\%}, respectively, following radiotherapy. Based on published reports these rates were higher than expected with observation alone. Conclusions: In the first 10 years Gleason score was the single most important predictor of death. Gleason score should be incorporated into the current clinical staging system.",
keywords = "Prostate neoplasms, Radiotherapy, Survival rate",
author = "Mack Roach and Jiandong Lu and Pilepich, {Miljenko V.} and Asbell, {Sucha O.} and Mohammed Mohiuddin and Roger Terry and David Grignon",
year = "1999",
month = "3",
doi = "10.1016/S0022-5347(01)61793-2",
language = "English (US)",
volume = "161",
pages = "864--868",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term survival after radiotherapy alone

T2 - Radiation Therapy Oncology Group prostate cancer trials

AU - Roach, Mack

AU - Lu, Jiandong

AU - Pilepich, Miljenko V.

AU - Asbell, Sucha O.

AU - Mohiuddin, Mohammed

AU - Terry, Roger

AU - Grignon, David

PY - 1999/3

Y1 - 1999/3

N2 - Purpose: We assess the relative importance of the several pretreatment characteristics in predicting death from prostate cancer in patients treated with curative intent with external beam radiotherapy alone. Materials and Methods: Patients entered on 4 prospective phase III randomized trials conducted by the Radiation Therapy Oncology Group between 1975 and 1992 were selected for this analysis if they were deemed evaluable and eligible for the trial, they had received no hormonal therapy with initial treatment and followup information was available. A disease specific survival event was declared if death was certified as due to prostate cancer, complications of treatment or unknown causes with clinically active malignancy. Median followup for patients treated on early and late studies exceeded 11 and 6 years, respectively. Results: Most of the patients (1,557) had tumors clinically staged as T3 (59%), and 87 (36%) with clinically staged T1-2 tumors had pathologically positive lymph nodes. On multivariate analysis Gleason score, clinical stage and nodal status were associated with a less favorable overall and disease specific survival, whereas others factors, such as age and race, were not. A Gleason score of 8 to 10 was associated with a high risk of dying of prostate cancer in the first 5 years (risk ratio 20.0, p = 0.0001). The 10-year disease specific survival for patients with a Gleason score of 2 to 5, 6 to 7 and 8 to 10 was 87, 75 and 44%, respectively, following radiotherapy. Based on published reports these rates were higher than expected with observation alone. Conclusions: In the first 10 years Gleason score was the single most important predictor of death. Gleason score should be incorporated into the current clinical staging system.

AB - Purpose: We assess the relative importance of the several pretreatment characteristics in predicting death from prostate cancer in patients treated with curative intent with external beam radiotherapy alone. Materials and Methods: Patients entered on 4 prospective phase III randomized trials conducted by the Radiation Therapy Oncology Group between 1975 and 1992 were selected for this analysis if they were deemed evaluable and eligible for the trial, they had received no hormonal therapy with initial treatment and followup information was available. A disease specific survival event was declared if death was certified as due to prostate cancer, complications of treatment or unknown causes with clinically active malignancy. Median followup for patients treated on early and late studies exceeded 11 and 6 years, respectively. Results: Most of the patients (1,557) had tumors clinically staged as T3 (59%), and 87 (36%) with clinically staged T1-2 tumors had pathologically positive lymph nodes. On multivariate analysis Gleason score, clinical stage and nodal status were associated with a less favorable overall and disease specific survival, whereas others factors, such as age and race, were not. A Gleason score of 8 to 10 was associated with a high risk of dying of prostate cancer in the first 5 years (risk ratio 20.0, p = 0.0001). The 10-year disease specific survival for patients with a Gleason score of 2 to 5, 6 to 7 and 8 to 10 was 87, 75 and 44%, respectively, following radiotherapy. Based on published reports these rates were higher than expected with observation alone. Conclusions: In the first 10 years Gleason score was the single most important predictor of death. Gleason score should be incorporated into the current clinical staging system.

KW - Prostate neoplasms

KW - Radiotherapy

KW - Survival rate

UR - http://www.scopus.com/inward/record.url?scp=0032826914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032826914&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)61793-2

DO - 10.1016/S0022-5347(01)61793-2

M3 - Article

VL - 161

SP - 864

EP - 868

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -